Rivaroxaban was approved for stroke prevention for non-valvular atrial fibrillation in 2011, with added advantage of decreased risk of bleeding in comparison to coumadin, made it a good alternative for coumadin. We report a case of severe subcapsular and intrarenal hematoma associated with Rivaroxaban in an elderly male with chronic kidney disease. He presented with severe left sided flank pain, shock and acute on chronic renal failure, he was successfully resuscitated with supportive care. We aim to alert primary care physicians, hospitalists, Emergency room physicians and cardiologists regarding the likelihood of encountering similar cases as the indications of direct acting oral anticoagulants are increasing and gaining more popularity in physicians and patients as well.
Keywords: Rivaroxaban; Renal hematoma; Shock
Published on: Dec 21, 2018 Pages: 4-6
Full Text PDF
Full Text HTML
DOI: 10.17352/ahcrr.000012
CrossMark
Publons
Harvard Library HOLLIS
Search IT
Semantic Scholar
Get Citation
Base Search
Scilit
OAI-PMH
ResearchGate
Academic Microsoft
GrowKudos
Universite de Paris
UW Libraries
SJSU King Library
SJSU King Library
NUS Library
McGill
DET KGL BIBLiOTEK
JCU Discovery
Universidad De Lima
WorldCat
VU on WorldCat
PTZ: We're glad you're here. Please click "create a new query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."